The NeurologyLive® MS Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with multiple sclerosis and demyelinating disorders.
The Expansion Toward Integrative Wellness Approaches in MS Care
Clinicians have begun to incorporate more holistic ways to approach the treatment of multiple sclerosis symptoms by focusing on better overall health, exercising, and dieting.
Pregnancy Does Not Affect Long-Term Disability Accumulation in MS
The cohort study was conducted using data from the Danish Multiple Sclerosis Registry for women with clinically isolated syndrome and relapsing remitting multiple sclerosis.
Disproportionate Neurodegeneration in Black Patients With MS: The Need for Stratified Treatments
Identifying the best treatment strategy for Black or African American patients who are at risk for a more challenging clinical course is of great importance and represents a key unmet need in our field.
The State of Biomarkers in Multiple Sclerosis
As the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.
Tolebrutinib Adds to the Growing Momentum of BTK Inhibitors in MS
The Bruton tyrosine kinase inhibitor has been evaluated in 2 phase 3 trials, GEMINI 1 and GEMINI 2 (NCT04410978; NCT04410991), in patients with relapsing-remitting and relapsing secondary progressive MS.
Advanced Practice Providers’ Perspectives on Optimal Multiple Sclerosis Management
In a NeurologyLive® Peer Exchange series, experts on the care of patients with multiple sclerosis offer recommendations for selecting and sequencing therapies used to treat patients with relapsing disease.
Moving Toward a More Personalized MS Treatment Journey
The field of MS is shifting focus to issues such as understanding and tracking disease progression, approaches to treatment initiation, and the roles of diet and exercise in pathogenesis and disease course.
MS Functional Connectivity Abnormalities Not Defined by One Brain Region
In cognitively impaired vs unimpaired patients, investigators found functional connectivity decreases in DMNa and DMNp and increases in the right and left frontoparietal networks.
Realistic Outlook for Mesenchymal Stem Cells, Other Treatments in Progressive MS: Jeffrey Cohen, MD
The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed when clinicians should anticipate new therapies to treat progressive MS. [WATCH TIME: 2 minutes]
Ocrelizumab Data Go Against Traditional Conceptions of Wearing Off Effect
Ilya Kister, MD, professor of neurology, NYU Grossman School of Medicine, discussed his surprising results from ECTRIMS, which found no evidence of wearing off with ocrelizumab (Ocrevus; Genentech).
Incorporation of Registered Dietitians in MS Care: Tyler Titcomb, PhD, RDN, IFMCP
The postdoctoral scholar at the University of Iowa commented on why the multiple sclerosis field should lean on registered dietitians to help alleviate symptoms of patients with multiple sclerosis. [WATCH TIME: 2 minutes]
Therapeutic Approaches to Fatigue in Multiple Sclerosis: Anna Kratz, PhD
Discussing cognitive behavioral therapy for patients with MS, the associate professor of Physical Medicine and Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine mentioned different therapeutic options that can benefit this patient population. [WATCH TIME: 3 minutes]
Why MS Clinicians Should Care More About Diet: Tyler Titcomb, PhD, RDN, IFMCP
The postdoctoral scholar at the University of Iowa discussed the importance of understanding more about the effects of diet and how it is managed when caring for a patient with multiple sclerosis. [WATCH TIME 3 minutes]
Anna Kratz, PhD, on Managing MS Fatigue in a Multifaceted Way
Anna Kratz, PhD, associate professor of Physical Medicine & Rehabilitation, University of Michigan Medicine, spoke to the benefits of a multifaceted approach to managing fatigue for patients with multiple sclerosis.
Strategies, Tools for Treating Fatigue in Multiple Sclerosis: Anna Kratz, PhD
The associate professor of Physical Medicine & Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine discussed challenges when addressing fatigue, as well as the need to integrate digital tools for patients with MS. [WATCH TIME: 4 minutes]
A Multidisciplinary Approach to Fatigue in Multiple Sclerosis: Anna Kratz, PhD
The associate professor of Physical Medicine & Rehabilitation and nonclinical research psychologist at University of Michigan Medicine discussed the complexities of fatigue as a symptom following her presentation at CMCS 2021.
Evaluating Ocrelizumab in the CHIMES Trial: Mitzi Joi Williams, MD
The founder and CEO of Joi Wellness Group Multiple Sclerosis Center described motivations behind the evaluation of ocrelizumab (Ocrevus; Genentech) in minority populations with multiple sclerosis.
Designing an MS Clinical Trial Focused on Minority Populations: Mitzi Joi Williams, MD
Outlining the development of the CHIMES trial in multiple sclerosis, the founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center spoke on tactics to get underrepresented populations involved. [WATCH TIME: 2 minutes]
Quality of Life Improvements in MS Following Wellness Program: Brian Hutchinson, PT, MSCS
The director of the Multiple Sclerosis Achievement Center in Sacramento discussed 3-year data from an assessment of the program, outlining key findings and future research efforts. [WATCH TIME: 6 minutes]
Discussing COVID-19 Vaccinations and Disease-Modifying Therapies in Multiple Sclerosis
Amit Bar-Or, MD, FRCPC, FAAN, FANA, commented on his presentations at CMSC 2021, one of which focused on COVID-19 vaccination, which experts do not believe poses risks for those on disease-modifying therapies.
Dietitians and the Multidisciplinary MS Care Team: Mona Bostick, RDN, LDN, MSCS
The founder of Food Matters 365, in Greensboro, North Carolina, commented on the benefits of adding a dietitian to the healthcare team for patients with multiple sclerosis. [WATCH TIME: 3 minutes]
Greater Health Inequities, Disparities in Demyelinating Disease Identified
Investigators highlighted the need to integrate research frameworks to analyze and understand these interrelationships, developing appropriate interventions for the Black, Latinx, and Hispanic populations with NMOSD and MS.
Ublituximab Biologics License Application Submitted for Relapsing MS
Application follows the results of 2 independent, identical phase 3 trials, ULTIMATE 1 and 2, which assessed the TG Therapeutics anti-CD20 antibody in more than 1000 patients.
Differences in Care for Millennial Patients With MS: Mitzi Joi Williams, MD
As the MS patient population includes more patients from the millennial generation, the founder and CEO of the Joi Life Wellness Group Multiple Sclerosis Center offered her insight on the way care differs for this generation compared with prior ones. [WATCH TIME: 4 minutes]
Effective Comprehensive Care Team Communication in MS: Patricia Bobryk, MHS, PT, MSCS, ATP
The physical therapist at UC Health and cochair of the International Organization of MS Rehabilitation Therapists discussed the importance of the care team for patients with MS and the role effective communication plays. [WATCH TIME: 4 minutes]
Treating Millennial Patients With Multiple Sclerosis
Mitzi Joi Williams, MD, shares her insights about differences in treatment and approach between millennial patients and the older generations of those with MS.
Episode 47: Incorporating Physical Therapy Into MS Care
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Patricia Bobryk, MHS, PT, MSCS, ATP.
EvoWalk Digital Therapy Platform Pilot Program Launched by Evolution Devices
Lisa Donahue PT, MPT, NCS, the director of Clinical Services at Evolution Devices, offered details about the EvoWalk platform, its potential in neurorehabilitation efforts, and its future clinical availability.
The Critical Nature of Patient-Focused MS Care: Patricia Bobryk, MHS, PT, MSCS, ATP
With the field of multiple sclerosis care focusing on the importance of patient-reported outcomes and shared decision-making, the physical therapist at UC Health and cochair of the International Organization of MS Rehabilitation Therapists offered commentary.
The Potential Need for a COVID-19 Vaccine Booster in Multiple Sclerosis
Joshua Katz, MD, commented on the possibility of an extra vaccine dose for patients with MS and experts’ hope to improve antibody response among the immunocompromised.
The Availability of MS Rehabilitation Therapists: Patricia Bobryk, MHS, PT, MSCS, ATP
Amid an ongoing national shortage of clinicians who treat neurologic diseases like MS, the cochair of the International Organization of MS Rehabilitation Therapists discussed the availability of rehabilitation professionals for patients.
Early Intervention With Physical Therapy for MS: Patricia Bobryk, MHS, PT, MSCS, ATP
The physical therapist at UC Health and cochair of the International Organization of MS Rehabilitation Therapists spoke to the current standards of rehabilitative care among patients with multiple sclerosis.
Disease-Modifying Therapies and COVID-19 Antibody Response: Joshua Katz, MD
The chairman of the Clinical Advisory Committee of the New England Chapter of the National MS Society addressed the role DMTs play in patient response to the COVID-19 vaccine.
The Potential COVID-19 Booster for Patients With MS: Joshua Katz, MD
The codirector of the Elliot Lewis Center for Multiple Sclerosis Care discussed the prospective COVID-19 vaccination booster and its implication for patients with MS.
FDA Approves Pfizer COVID-19 Vaccine for Those Ages 16 Years and Older
The full approval for BNT162b2 (Comirnaty; Pfizer/BioNTech) will afford physicians greater prescribing capability and is expected to play a role in driving workplace vaccine mandates.
6-Week Dosing of Natalizumab Effective, May Reduce PML Risk
Efficacy data from a trial examining extended dosing adds to real-world data that demonstrates a significant reduction in the probability of progressive multifocal leukoencephalopathy infection.
Pfizer COVID-19 Vaccine Continues to Show Real-World Safety in Multiple Sclerosis
Of those who reported new or worsening neurological symptoms, 77.8% didn’t require any additional medication to treat their symptoms.
Cutting Edge Care in Multiple Sclerosis: Advances in S1P Therapy
Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).
Differentiating Treatment Regimens Based on Diagnosis vs Personal Needs: Barry Hendin, MD
The neurologist from Banner Health and chief medical officer of the MS Association of America discussed how much a patients prognosis plays into the treatments utilized.
Patients With MS on Rituximab at Higher Risk for COVID-19 Hospitalization
While rituximab treatment puts patients at a higher risk for infectious disease in general, use of such treatment poses particular risk for severe COVID-19 infections in patients with MS.
MRI Characteristics Reflect Specific MS Immunopatterns
Instead of a smooth-contoured, thin, and regular ring or arc typically seen, pattern 3 patients had atypical rings such as irregularly thick rings and arcs.
Biogen and InnoCare Reach Collaboration Agreement for BTK Inhibitor Orelabrutinib
Orelabrutinib has the potential to inhibit B cell and myeloid cell effector functions in the central nervous system and may provide a clinically meaningful benefit on progression in all forms of MS.
Long-Term Disability Linked to Prior MS Relapses in Pregnant Women
Longer exposure to disease-modifying therapy over the follow-up period reduced the risk of disability worsening among pregnant people with multiple sclerosis.
Atrophied Lesion Volume as a Biomarker of Disability in Progressive Multiple Sclerosis
Robert Zivadinov, MD, PhD, director, Buffalo Neuroimaging Analysis Center, spoke to the findings of a post-hoc analysis of atrophied T2-lesion volume as a biomarker in patients with progressive MS.
Ublituximab Demonstrates Greater Efficacy in Relapsing MS Over Teriflunomide
A significantly higher percentage of patients treated with ublituximab compared to those on teriflunomide achieved no evidence of disease activity status.
Worsened Cognition in Multiple Sclerosis Related to Ventral Attention Network
At baseline, a negative correlation was noted between average cognition and VAN importance in both groups, indicating that lower VAN importance is related to a higher average cognition.
Developing Cell Therapy for Progressive MS: Jakob Dupont, MD, MA
The head of global research and executive vice president of Atara Biotherapeutics discussed the upcoming study evaluating ATA188.
MRI in Multiple Sclerosis Guidelines Update: North America, Europe Align on New Recommendations
These consensus guidelines are significant not only for their key updates to clinical practice but for their representation of a more unified, global approach to diagnosing and monitoring patients with multiple sclerosis.
Episode 38: Advancing MS Care and Awareness
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Barry Hendin, MD.
Better Measuring Upper-Extremity Issues in Patients With MS
Marisa McGinley, DO, from the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic, offered her insight into the manual dexterity test and the need to better prognosticate dexterity issues.
Evaluating ATA188 in Progressive MS: Jakob Dupont, MD, MA
The head of global research and executive vice president of Atara Biotherapeutics discussed the trial design of part 2 of the study of ATA188.
Evaluating the aT2-LV Biomarker for MS: Robert Zivadinov, MD, PhD
The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed the findings of the post-hoc analysis of the ORATORIO study.
A Call to Action for Progressive MS Research: Kathy Zackowski, PhD, OTR
The senior director of patient management, care, and rehabilitation research at the National Multiple Sclerosis Society encouraged clinicians to spread word of the need for research.
Relapsing and Progressive MS Both Impacted by Environmental and Lifestyle Factors
Environmental factors such as smoking, alcohol consumption, overweight/obese status, and sun exposure were associated with an increased risk of relapsing-onset and progressive-onset MS.
B-Cell Depletion a Factor in SARS-CoV-2 Antibody Response in Multiple Sclerosis
All patients treated with ocrelizumab (Ocrevus; Genentech) were B-cell depleted and had lower SARS-CoV-2 antibody response than any other patients in the study.
Better Defining Multiple Sclerosis Categorization: Daniel Ontaneda, MD, PhD
The associate professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University discussed the potential of a data-driven approach to classifying patients with MS.
Treatment Improvements for Pediatric-Onset MS Have Reduced Risk of Persistent Disability
Improvements in DMTs and management standards appear to have lowered the risk of progression to EDSS scores of 4.0 and 6.0 for those with pediatric-onset disease.
Clinical Utility of Manual Dexterity Test in MS: Marisa McGinley, DO
The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how novel dexterity measurements can improve prognostication of disease progression.
Data-Driven Categorization of Patients With Multiple Sclerosis: Daniel Ontaneda, MD, PhD
The associate professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University discussed the findings of his presentation at AAN 2021.
Biomechanical Measures of Upper Extremity Function in MS: Marisa McGinley, DO
The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic spoke to a study using the digital Manual Dexterity Test.
Despite Early Signs of Multiple Sclerosis, Diagnosis Often Occurs Years Later
Before first diagnosis, patients with multiple sclerosis had more frequent encounters with medical doctors of different specialties compared to matched controls.
Active MRIs Pre-Pregnancy Predict Postpartum Relapse in MS
Researchers also found that EDSS score pre-pregnancy was associated with the likelihood of post-partum relapse for patients with multiple sclerosis.
Microglia’s Role in MS and Other Neurodegenerative Diseases: Daniel Reich, MD, PhD
The senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about new opportunities for research into brain lesions and microglia.
Targeting Progressive MS Symptoms: Kathy Zackowski, PhD, OTR
The senior director of patient management, care, and rehabilitation research at the National MS Society discussed symptoms of MS that need more research, as well as other factors impacting care, such as comorbidities.
Switch to Siponimod Safe, Tolerable With No Washout, Study Finds
Results from the ongoing clinical trial will help define clinical management guidelines for switching patients with relapsing MS on other disease-modifying therapies to siponimod.
Personalized Cladribine Dosing for Multiple Sclerosis
Kimberly Allen-Philbey, a PhD candidate at the Barts MS Center in London, discussed the advantages of using a personalized dosing schedule of off-label, subcutaneous cladribine.
Rituximab Modulates Retinal Atrophy in Relapsing-Remitting Multiple Sclerosis
Findings suggest that the neuroprotective therapeutic response from rituximab in patients with relapsing-remitting multiple sclerosis may take up to 12 months.
Finding New Therapeutic Targets in MS: Daniel Reich, MD, PhD
The senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about further research his lab is conducting into MS mechanisms.
Crucial Symptoms of Progressive MS: Kathy Zackowski, PhD, OTR
The senior director of patient management, care, and rehabilitation research at the National MS Society discussed symptoms of progressive MS that need more attention and research.
Potential Use of DISCO-MS Survey: Anne Kever, PhD
The postdoctoral researcher at Columbia University discussed the use of the DISCO-MS survey and its potential for future research projects.
Does Early DMT Prescription Prevent Conversion to Clinically Definite Disease?
Ilena George, MD, of Massachusetts General Hospital, discussed a cohort of patients with early DMT prescription and low rates of clinical conversion.
Increased Risks With Alemtuzumab Following Fingolimod Treatment in Multiple Sclerosis
Treatment with fingolimod followed by alemtuzumab led to an increase in spinal relapses as well as increased risk of secondary autoimmunity.
The Rarity of Adverse Events With Natalizumab Infusion for MS
Yujie Wang, MD, a neurologist from the University of Washington Medical Center, discussed examining the 1-hour post monitoring period of natalizumab infusion amid the COVID-19 pandemic.
Ponesimod Superior to Teriflunomide Across Multiple MS Outcomes
Annualized relapse rate reduction, fatigue, magnetic resonance imaging activity, brain volume loss, and no evidence of disease activity status were all superior in the ponesimod-treated group.
The Need for Progressive MS Research: Kathy Zackowski, PhD, OTR
The senior director of patient management, care, and rehabilitation research at the National MS Society discussed the lack of studies on progressive MS compared to RRMS.
Myelin Cervical Cord Abnormalities Can Serve as Marker of MS Progression
Researchers found significant differences between clinically relevant areas in participants with progressive MS, relapsing MS, and healthy controls.
Predicting MS Disability: IL-1 Receptor Antagonist or Neurofilament Light?
Stephanie Blandford, MSc, a PhD candidate at Memorial University of Newfoundland, discussed some advantages of using IL-1RA over NfL in predicting disability in multiple sclerosis.
To Treat or Not to Treat: Secondary Progressive and Primary Progressive MS
Progressive forms of multiple sclerosis present a number of challenges for MS specialists, the biggest of which being whether or not disease-modifying therapy is required.
Portable Neuromodulation Stimulator Device for MS Gait Deficit Wins Approval
The PoNS device becomes the first and only medical device cleared in the US for short-term treatment of gait in patients with multiple sclerosis.
Serum GFA Protein: An Accurate Biomarker for Neuromyelitis Activity, Attack Risk
Researchers analyzed levels of sGFAP in participants from the N-MOmentum study that assessed inebilizumab (Uplizna; Viela Bio) in relapsing-remitting MS.
Plasma NfL Levels Predict NEDA-BVL Status as an MS Biomarker
Researchers from Pavol Jozef Šafárik University, Košice, Slovakia, found that plasma neurofilament light levels predict no evidence of disease activity status as well as NEDA plus brain volume loss status.
Siponimod Offers Benefit to Cognitive Processing Speed in SPMS
Siponimod (Mayzent; Novartis) improved Symbol Digit Modalities Test scores in patients at 12, 18, and 24 months compared to placebo.
Siponimod Reduces Risk of Disability Progression Regardless of Prior Relapses in MS
The Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.
Siponimod Shows EDSS Subscale Benefits in Secondary Progressive MS
Novartis’s S1P receptor modulator siponimod (Mayzent) showed benefits in a number of patients with SPMS on the Motor Integration and Collateral subscales of the Expanded Disability Status Scale.
Siponimod Shows Long-Term Benefit for Secondary Progressive MS
Five-year EXPAND study data suggest that Novartis’s S1P receptor modulator has sustained benefit and delays disability over long-term treatment in patients with SPMS.
What Role Does Age Play in Multiple Sclerosis?
The director of the Multiple Sclerosis Program at Cleveland Clinic Lou Ruvo Center for Brain Health discussed the correlation between age and disease duration in MS, as well as what was learned from a subanalysis of the EXPAND study of siponimod.
Siponimod Significantly Slows MS Disability Progression in Patients With Shorter Disease Duration
Patients with a disease duration of
Siponimod Delays Time to Wheelchair Use in Secondary Progressive MS
After showing significant benefits in delayed disease progression in patients with secondary progressive MS, new data suggests siponimod can delay the time to wheelchair dependence by 4 years.
Siponimod Cleared for Treatment of Secondary Progressive MS
Marketed as Mayzent, the selective sphingosine 1-phosphate receptor modulator is the first treatment for patients with active secondary progressive multiple sclerosis in almost 15 years.
Siponimod NDA Accepted by FDA for Secondary Progressive MS
If approved, siponimod would be the first oral disease-modifying therapy with the potential to delay secondary progressive multiple sclerosis progression.
2 Clarke Drive Cranbury, NJ 08512